- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04336150
Pelvic Floor Muscle Contraction During Hypopressive Exercise in Women With Pelvic Floor Dysfunction (HIPOSPFD)
Effects of Voluntary Pelvic Floor Muscle Contraction During Different Modalities of Hypopressive Exercise in Women With Pelvic Floor Dysfunction: A Randomized Controlled Trial
Study Overview
Status
Conditions
Detailed Description
This is a four-arm, parallel-group randomized controlled trial conducted in women with pelvic floor dysfunction. Participants are randomly allocated to one of four intervention groups combining different components of hypopressive exercise: the hypopressive manoeuvre performed within the specific postural programme traditionally used in hypopressive exercise, with or without voluntary pelvic floor muscle contraction; or the hypopressive manoeuvre performed without the specific postural programme, with or without voluntary pelvic floor muscle contraction.
All interventions are delivered individually under physiotherapist supervision and include an educational component addressing the anatomy and physiology of the abdominopelvic cavity and pelvic floor, together with hygienic and behavioural recommendations for the prevention and management of pelvic floor dysfunction.
The hypopressive manoeuvre consists of expiration followed by expiratory apnoea and active rib-cage expansion without inhalation, accompanied by inward and cranial displacement of the abdominal wall. In the groups using the specific hypopressive postural programme, the manoeuvre is incorporated into a sequence of postures performed in different body positions according to the principles of Hypopressive Abdominal Gymnastics.
In the groups performing the hypopressive manoeuvre without the specific postural programme, real-time transabdominal ultrasound imaging is used as visual biofeedback to facilitate motor learning and contraction of the transversus abdominis muscle during performance of the manoeuvre.
Interventions are performed twice weekly in individually supervised 45-minute sessions. Participants following the specific hypopressive postural programme receive 16 sessions over 8 weeks, whereas participants performing the hypopressive manoeuvre without the specific postural programme receive 12 sessions over 6 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Alcalá de Henares, Madrid, Spain, 28005
- María
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women diagnosed with pelvic floor dysfunction by their doctor.
- With minimum strength of the pelvic floor muscles of 3 according to Modified Oxford Score
Exclusion Criteria:
- Women who are pregnant or women who have had a vaginal or caesarean birth in the past six months.
- Women whose PFD is severe and the first indication is surgical (POP-Q grade III-IV prolapses).
- Women with only urinary incontinence or fecal urgency.
- Women with pain in the pelvic-perineal region of 3 cm in the visual analog scale, where a score of 0 cm means no pain, and a score of 10cm, the maximum pain that the participant can imagine.
- Women who have received pelvic floor physiotherapy treatment in the last 12 months.
- Women who are unable to voluntarily contract the pelvic floor muscles, quantified by the Modified Oxford Score by a score less than or equal to 2.
- Women with any pathology that may affect the treatment (neurological, gynecological or urological), or with recurrent urinary infection or hematuria.
- Women with cognitive limitations to understand the information, answer the questionnaires, consent and / or participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hypopressive exercises&PFM contraction
Hypopressive exercises + active pelvic floor muscle contraction:
|
See information included in arm/group descriptions.
|
|
Experimental: Hypopressive maneuver
Hypopressive maneuver:
|
See information included in arm/group descriptions.
|
|
Experimental: Hypopressive maneuver&PFM contraction
Hypopressive maneuver + pelvic floor muscles contraction:
|
See information included in arm/group descriptions.
|
|
Experimental: Hypopressive exercises
Hypopressive exercises described according to Dr. Caufriez
|
See information included in arm/group descriptions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in life impact of pelvic floor dysfunction
Time Frame: 4 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 month and 6 months after the intervention.
|
It will be assessed by the PFIQ-7 Spanish version.
The PFIQ-7 consists of 3 scales of 7 questions each taken from the Urinary Impact Questionnaire, the Pelvic Organ Prolapse Impact Questionnaire, and the Colorectal-Anal Impact Questionnaire.
The 3 scales are scored from 0 (least impact) to 100 (greatest impact) and an overall summary score (0 to 300).
|
4 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 month and 6 months after the intervention.
|
|
Change in symptoms and quality of life: PFDI-20
Time Frame: 4 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
It will be assessed by PFDI-20 that is both a symptom inventory and a measure of the degree of bother and distress caused by pelvic floor symptoms.
The PFDI-20 includes 20 questions and 3 scales.
Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress).
The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300 and the higher the score, the worse quality of life.
The 3 scales include questions taken from the following widely used outcome measures: Urinary Distress Inventory - 6 questions, Pelvic Organ Prolapse Distress Inventory - 6 questions, and Colorectal-Anal Distress Inventory - 8 questions collecting data about UI, POP and colorectal and anal symptoms.
|
4 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in pelvic floor muscle strength by dinamometry
Time Frame: 4 assessments to evaluate change from baseline after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
It will be measured by dynamometry (measured in GRAMS).
|
4 assessments to evaluate change from baseline after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
|
Change in pelvic floor muscle pasive tone
Time Frame: 4 assessments to evaluate change from baseline after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
It will be measured by dinamometry (measured in GRAMS)
|
4 assessments to evaluate change from baseline after the intervention period (2 months from baseline), 3 months and 6 months after the intervention.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: María Torres-Lacomba, PhD, University of Alcala
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OE13/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.